Gabelli Funds LLC Global Blood Therapeutics, Inc. Transaction History

Gabelli Funds LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$32.4 - $68.18 $13.4 Million - $28.2 Million	413,178 Added 2151.97%	432,378 $29.4 Million
Q2 2022 Aug 12, 2022	BUY	$22.3 - $37.39 $4,460 - $7,478	200 Added 1.05%	19,200 $613,000
Q4 2021 Feb 11, 2022	SELL	$24.9 - $40.26 $219,717 - $355,254	-8,824 Reduced 31.71%	19,000 $556,000
Q3 2021 Nov 12, 2021	SELL	$25.48 - $37.34 $484,120 - $709,460	-19,000 Reduced 40.58%	27,824 $709,000
Q2 2021 Aug 13, 2021	BUY	$32.46 - $43.42 $665,430 - $890,110	20,500 Added 77.88%	46,824 $1.64 Million
Q1 2021 May 14, 2021	BUY	$38.94 - $50.85 $1.03 Million - $1.34 Million	26,324 New	26,324 $1.07 Million
Q4 2019 Feb 14, 2020	SELL	$45.7 - $81.86 $548,400 - $982,320	-12,000 Closed	0 $0
Q4 2018 Jan 30, 2019	SELL	$31.54 - $46.67 $63,080 - $93,340	-2,000 Reduced 14.29%	12,000 $493,000
Q3 2018 Nov 02, 2018	BUY	$38.0 - $51.1 $95,000 - $127,750	2,500 Added 21.74%	14,000 $532,000
Q2 2018 Aug 10, 2018	BUY	$38.7 - $50.15 $174,150 - $225,675	4,500 Added 64.29%	11,500 $520,000
Q1 2018 May 09, 2018	BUY	$39.6 - $65.9 $277,200 - $461,300	7,000 New	7,000 $338,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Gabelli Funds LLC, based on Form 13F filings with the SEC.

Stay updated on Gabelli Funds LLC with notifications on news.